SCHEMBL2863469

SCHEMBL2863469

OCCN(CCO)c1ncc(-c2cccc(Nc3cc(Cl)ccn3)n2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.47
KARS1 Q15046 7/20 0.39
CDK1 P06493 3/20 0.39
KDR P35968 2/20 0.39
TYK2 P29597 1/20 0.35
CDK7 P50613 2/20 0.34
CHEK1 O14757 1/20 0.34
GRM4 Q14833 1/20 0.33
CDK5 Q00535 3/20 0.33
CDK5R1 Q15078 3/20 0.33
NPC1 O15118 2/20 0.33
MAPT P10636 2/20 0.33
XBP1 P17861 2/20 0.33
MAPK1 P28482 2/20 0.33
HTT P42858 2/20 0.33
RAB9A P51151 2/20 0.33
ATM Q13315 1/20 0.33
CCNT1 O60563 1/20 0.33
CDK4 P11802 1/20 0.33
CCNB1 P14635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2858598 0.88 KARS1 (0.53) SYKKARS1KDRNPC1RAB9A
SCHEMBL2868048 0.79 KARS1 (0.53) SYKKARS1KDRNPC1RAB9A
SCHEMBL2866084 0.77 SYK (0.52) SYKKARS1CDK1KDRCDK7
SCHEMBL2868901 0.75 SYK (0.49) SYKCDK9
SCHEMBL13136462 0.74 SYK (0.46) SYKKARS1KDR
SCHEMBL2866358 0.73 SYK (0.51) SYKCDK1KDRCHEK1CDK4
SCHEMBL13136499 0.73 SYK (0.50) SYKKARS1KDR
SCHEMBL2859263 0.73 KARS1 (0.49) SYKKARS1KDRNPC1RAB9A
SCHEMBL2872347 0.72 KARS1 (0.48) SYKKARS1KDRNPC1RAB9A
SCHEMBL2861389 0.72 SYK (0.52) SYKKARS1TYK2CDK7CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US claimed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP claimed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US claimed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP disclosed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP disclosed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity SYK, BTK, ZAP70 SYK 1/4885KARS1 2175/4885CDK1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.